Natural killer cels in immunotherapy for cancer
https://doi.org/10.21294/1814-4861-2018-17-6-97-104
Abstract
Cancer is the second leading cause of death worldwide behind cardiovascular diseases. Late stage of cancer at diagnosis and low efficacy of traditional cancer treatments result in low survival rate in cancer patients. Modern techniques to kill tumor cells are therefore needed. Over the last decade novel anticancer treatments have emerged from advances in our understanding of tumor cell biology, and a number of molecular and biologic targets have been identified. Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy, which is used predominantly in the treatment of hematological malignancies. Moreover, it has been evidenced that cells of the innate immune system are key players at initiating and regulating adaptive immune responses. Studies focusing on innate immune cells for cancer immunotherapy show promising results. In this review, we describe functions of natural killer cells and analyze the rationale for using natural killer cells in cancer therapy.
About the Authors
E. A. Borobova
E.N. Meshalkin National Medical Research Center; Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
Elena A. Borobova - MD, Clinical Laboratory Scientist E.N. Meshalkin NMRC; Researcher, State Research Center of Virology and Biotechnology «Vector».
15, Rechkunovskaya Street, 630055-Novosibirsk; Koltsovo-630559, Novosibirsk Region
A. A. Zheravin
E.N. Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Alexander A. Zheravin - MD, PhD, Head of Oncology and Radiotherapy Department.
15, Rechkunovskaya Street, 630055-Novosibirsk
References
1. Kaprin A.D., Starinsky V.V., Petrov G.V. Malignant neoplasms in Russia in 2016. Moscow, 2018. 4-5. (in Russian).
2. Strauss-AlbeeD.M., Fukuyama J., LiangE.C., Yao Y., Jarrell J.A., Drake A.L., Kinuthia J., Montgomery R.R., John-Stewart G., Holmes S., Blish C.A. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. 2015 Jul 22; 7 (297): 297ra115. doi: 10.1126/scitranslmed.aac5722.
3. Mistry A.R., O’Callaghan C.A. Regulation of ligands for the activating receptor nkg2d. Immunology. 2007; 121 (4): 439-47. doi: 10.1111/j.1365-2567.2007.02652.x.
4. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000 Nov 25; 356 (9244): 1795-9. doi: 10.1016/S0140-6736(00)03231-1.
5. Schreiber R.D., OldL.J., SmythMJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011 Mar 25; 331 (6024): 1565-70. doi: 10.1126/science.1203486.
6. Lakshmikanth T, BurkeS.,Ali T.H., Kimpfler S., UrsiniF, RuggeriL., Capanni M., Umansky V, Paschen A., Sucker A., Pende D., Groh V, Bias-soni R., Hoglund P., Kato M., Shibuya K., Schadendorf D., Anichini A., Ferrone S., Velardi A., Karre K., Shibuya A., Carbone E., Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009 May; 119 (5): 1251-63. doi: 10.1172/JCI36022.
7. Borrego F, Larrucea S., Solana R., Tarazona R. NK cell-based cancer immunotherapy. Front Immunol. 2016 Jun 27; 7: 249. doi: 10.3389/ fimmu.2016.00249.
8. ChengM., Chen Y., Xiao W., Sun R., Tian Z. nk cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013 May; 10 (3): 230-52. doi: 10.1038/cmi.2013.10.
9. Zhang T., LemoiB.A., Sentman C.L. chimeric NK-receptor-bearing t cells mediate antitumor immunotherapy. Blood. 2005; 106 (5): 1544-51. doi: 10.1182/blood-2004-11-4365.
10. Barber A., Rynda A., Sentman C.L. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009 Dec 1; 183 (11): 6939-47. doi: 10.4049/jimmunol.0902000.
11. WaldhauerI., SteinleA. nk cells and cancer immunosurveillance. Oncogene. 2008 Oct 6; 27 (45): 5932-43. doi: 10.1038/onc.2008.267.
12. CarlstenM., Norell H., Bryceson Y.T., Poschke I., Schedvins K., Ljunggren H.G., Kiessling R., Malmberg K.J. Primary human tumor cells expressing cd155 impair tumor targeting by down-regulating dnam-1 on nk cells. J Immunol. 2009 Oct 15; 183 (8): 4921-30. doi: 10.4049/jimmunol.0901226.
13. El-Sherbiny Y.M., Meade J.L., Holmes T.D., McGonagleD.,Mac-kie S.L., Morgan A.W., Cook G., Feyler S., Richards S.J., Davies F.E., Morgan G.J., Cook G.P. The requirement for dnam-1, nkg2d, and nkp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007; 67 (18): 8444-9. doi: 10.1158/0008-5472.can-06-4230.
14. Sanchez-CorreaB., GayosoI., Bergua JM., Casado J. G., MorgadoS., Solana R., Tarazona R. Decreased expression of dnam-1 on nk cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012 Jan; 90 (1): 109-15. doi: 10.1038/icb.2011.15.
15. O’Leary J.G., Goodarzi M., Drayton D.L., von Andrian U.H. T cell- and b cell-independent adaptive immunity mediated by natural killer cells. nature immunology. 2006; 7 (5): 507-16. doi: 10.1038/ni1332.
16. Paust S., von Andrian U.H. Natural killer cell memory. Nature Immunology. 2011; 12 (6): 500-8.
17. Sun J.C., Beilke J.N., Lanier L.L. Adaptive J immune features of natural killer cells. Nature. 2009 Jan 29; 457 (7229): 557-61. doi: 10.1038/nature07665.
18. Sun J.C., Beilke J.N., Lanier L.L. J immune memory redefined: characterizing the longevity of natural killer cells. Immunol Rev. 2010 Jul; 236: 83-94. doi: 10.1111/j.1600-065X.2010.00900.x.
19. Ni J., MillerM., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of il-12/15/18-preactivated nk cells against established tumors. J Exp Med. 2012 Dec 17; 209 (13): 2351-65. doi: 10.1084/jem.20120944.
20. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis FP, Leitman S., Linehan W.M., Robertson C.N., LeeR.E., Rubin J.T. A progress report on the treatment of 157 patients with advanced cancer using lym-phokine-activated killer-cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9; 316 (15): 889-97.
21. Suck G., Linn Y.C., Tonn T. Natural killer cells for therapy of leukemia. Transfus Med Hemother. 2016 Mar; 43 (2): 89-95. doi: 10.1159/000445325.
22. Shubina I.J., Chikil-eva I.O., Mikhailova I.N., DemidovL.V., OgorodnikovaE.V., Tazaev VN., KiselevskyM.V. Activated nk cells for cell-based immunotherapy. Russian immunological journal. 2012; 6 (15) 1: 71-9. (in Russian).
23. SmythM.J., CretneyE., KershawM.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004; 202: 275-93. doi: 10.1111/j.0105-2896.2004.00199.x.
24. Oberlies J., Watzl C., Giese T., Luckner C., Kropf P., Muller I., Ho A.D., Munder M. Regulation of nk cell function by human granulocyte arginase. J Immunol. 2009 May 1; 182 (9): 5259-67. doi: 10.4049/ jimmunol.0803523.
25. LeivasA., Perez-MartinezA., BlanchardM.J., Martin-ClaveroE., Fernandez L., Lahuerta J.J., Martinez-Lopez J. Novel treatment strategy with autologous activated and expanded natural killer cells plus antimyeloma drugs for multiple myeloma. Oncoimmunology. 2016 Nov 22; 5 (12): e1250051. doi: 10.1080/2162402X.2016.1250051.
26. Ruggeri L., CapanniM., Urbani E., PerruccioK., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002 Mar 15; 295 (5562): 2097-100. doi: 10.1126/science.1068440.
27. RuggeriL., MancusiA., PerruccioK., BurchielliE., MartelliM.F., Velardi A. Natural killer cell alloreactivity for leukemia therapy. J Immu-nother. 2005; 28 (3): 175-82. doi: 10.1097/01.cji.0000161395.88959.1f.
28. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns LJ., OrchardP.J., BlazarB.R., Wagner J.E., SlungaardA., Weisdorf D.J., Okazaki I.J., McGlaveP.B. Successful adoptive transfer and in vivo expansion of human haploidentical nk cells in patients with cancer. Blood. 2005 Apr 15; 105 (8): 3051-7. doi: 10.1182/blood-2004-07-2974.
29. Denman C.J., Senyukov VV, Somanchi S.S., Phatarpekar P.V., Kopp LM., Johnson J.L., Singh H., Hurton L., Maiti S.N., Huls M.H., Champlin R.E., Cooper L.J., Lee D.A. Membrane-bound il-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012; 7 (1): e30264. doi: 10.1371/journal.pone.0030264.
30. Fujisaki H., Kakuda H., Imai C., Mullighan C.G., Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009 Jun; 145 (5): 606-13. doi: 10.1111/j.1365-2141.2009.07667.x.
31. Lapteva N., Durett A.G., Sun J., Rollins L.A., Huye L.L., Fang J., Dandekar V, Mei Z., Jackson K., Vera J., Ando J., Ngo M.C., Coustan-Smith E., Campana D., Szmania S., Garg T., Moreno-Bost A., Vanrhee F., Gee A.P., Rooney C.M. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14 (9): 1131-43. doi: 10.3109/14653249.2012.700767.
32. Chu Y., Ayello J., Hochberg J., Murphy J., Stier A., Cairo M.S. Genetically engineered natural killer (nk) cell immunotherapy for poor risk b-cell (cd20(+)) leukemia and lymphoma (l/l). Cancer Res. 2012; 72. doi: 10.1158/1538-7445.am2012-3511.
33. Arai S., MeagherR., SwearingenM., MyintH., RichE., Martin-son J., Klingemann H. J infusion of the allogeneic cell line nk-92 in patients with advanced renal cell cancer or melanoma: a phase i trial. Cytotherapy. 2008; 10 (6): 625-32. doi: 10.1080/14653240802301872.
34. Tonn T., SchwabeD., KlingemannH.G., Becker S., EsserR., Koehl U., Suttorp M., SeifriedE., Ottmann O.G., Bug G. Treatment of patients with advanced cancer with the natural killer cell line nk-92. Cytotherapy. 2013 Dec; 15 (12): 1563-70. doi: 10.1016/j.jcyt.2013.06.017.
35. Hinrichs C.S., Rosenberg S.A. Exploiting the curative potential of adoptive t-cell therapy for cancer. immunological reviews. 2014; 257 (1): 56-71. doi: 10.1111/imr.12132.
36. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-cd20 monoclonal antibody and polymorphism in igg fc receptor fc gamma riiia gene. Blood. 2002; 99 (3): 754-8. doi: 10.1182/blood.v99.3.754.
37. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., Neri TM., Ardizzoni A. Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with her-2/ neu-positive metastatic breast cancer. J Clin Oncol. 2008 Apr 10; 26 (11): 1789-96. doi: 10.1200/JC0.2007.14.8957.
38. Taylor R.J., Chan S.L., Wood A., Voskens C.J., WolfJ.S., Lin W., ChapovalA., SchulzeD.H., Tian G., Strome S.E. Fcgamma riiia polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2009 Jul; 58 (7): 997-1006. doi: 10.1007/s00262-008-0613-3.
39. Zhang W., GordonM., SchultheisAM., YangD.Y., NagashimaF., Azuma M., Chang HM., Borucka E., Lurje G., Sherrod A.E., Iqbal S., Groshen S., Lenz H.J. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25 (24): 3712-8. doi: 10.1200/JCO.2006.08.8021.
40. Schonfeld K., Sahm C., Zhang C., Naundorf S., Brendel C., Odendahl M., Nowakowska P., Bonig H., Kohl U., Kloess S., Kohler S., Holtgreve-Grez H., Jauch A., Schmidt M., Schubert R., Kuhlcke K., Seifried E., Klingemann H.G., Rieger M.A., Tonn T., Grez M., Wels W.S. Selective inhibition of tumor growth by clonal nk cells expressing an erbb2/ her2-specific chimeric antigen receptor. molecular therapy. 2015; 23 (2): 330-8. doi: 10.1038/mt.2014.21.
41. Romanski A., Uherek C., Bug G., Seifried E., Klingemann H., Wels W.S., Ottmann O.G., Tonn T. CD19-car engineered nk-92 cells are sufficient to overcome nk cell resistance in b-cell malignancies. Journal of cellular and molecular medicine. 2016; 20(7): 128794. doi: 10.1111/jcmm.12810.
Review
For citations:
Borobova E.A., Zheravin A.A. Natural killer cels in immunotherapy for cancer. Siberian journal of oncology. 2018;17(6):97-104. (In Russ.) https://doi.org/10.21294/1814-4861-2018-17-6-97-104
Views:
3676
Email this article 
